ProfileGDS4814 / ILMN_2053536
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 72% 68% 72% 68% 67% 67% 70% 71% 67% 68% 70% 70% 70% 65% 70% 65% 69% 65% 69% 72% 71% 67% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)80.364372
GSM780708Untreated after 4 days (C2_1)66.591568
GSM780709Untreated after 4 days (C3_1)81.014172
GSM780719Untreated after 4 days (C1_2)68.350268
GSM780720Untreated after 4 days (C2_2)63.842767
GSM780721Untreated after 4 days (C3_2)64.531867
GSM780710Trastuzumab treated after 4 days (T1_1)73.084770
GSM780711Trastuzumab treated after 4 days (T2_1)76.389371
GSM780712Trastuzumab treated after 4 days (T3_1)64.33367
GSM780722Trastuzumab treated after 4 days (T1_2)67.118168
GSM780723Trastuzumab treated after 4 days (T2_2)74.380370
GSM780724Trastuzumab treated after 4 days (T3_2)72.752470
GSM780713Pertuzumab treated after 4 days (P1_1)72.557770
GSM780714Pertuzumab treated after 4 days (P2_1)61.145465
GSM780715Pertuzumab treated after 4 days (P3_1)74.6770
GSM780725Pertuzumab treated after 4 days (P1_2)60.851665
GSM780726Pertuzumab treated after 4 days (P2_2)69.52269
GSM780727Pertuzumab treated after 4 days (P3_2)60.672465
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)71.049769
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)81.031372
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)77.714971
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)65.426767
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)65.208667